Reckitt Benckiser withdraws Reuters’ $ 1.4 billion charge to individuals for US opioid probes
(Reuters)-Indivior tells Detormakers on Monday that former parent Reckitt Benckiser withdrew its $ 1.4 billion claim to end a court battle related to a US investigation into opioid addiction. He said he would pay the dollar.
According to a London-listed pharmaceutical company, the two companies have also agreed to withdraw all liability from each other, and Indivior will not seek damages related to the settlement with the US Department of Justice and the Federal Trade Commission.
Reckitt Benckiser to resolve allegations that former pharmaceutical business Indiviol has implemented an illegal plan in the United States to boost sales of Sboxon, a film version of an opioid addiction drug. We have agreed to pay up to $ 1.4 billion in 2019.
A long-term US survey began long before Indiviol was spun out from Reckitt Benckiser in 2014.
Indivior was indicted in early 2019 and accused of deceiving doctors and medical benefit programs through various schemes to believe that treatments, a type of opioid, are safer and less abused than similar drugs.
Fusion media Alternatively, anyone involved in Fusion Media will not be liable for any loss or damage resulting from relying on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with trading in financial markets. This is one of the most risky forms of investment possible.
Reckitt Benckiser withdraws Reuters’ $ 1.4 billion charge to individuals for US opioid probes
https://www.investing.com/news/stock-market-news/reckitt-withdraws-14-billion-claim-against-indivior-2398036 Reckitt Benckiser withdraws Reuters’ $ 1.4 billion charge to individuals for US opioid probes
